RU2011117160A - Хиназолинон, хинолон и родственные аналоги в качестве модуляторов сиртутуина - Google Patents
Хиназолинон, хинолон и родственные аналоги в качестве модуляторов сиртутуина Download PDFInfo
- Publication number
- RU2011117160A RU2011117160A RU2011117160/04A RU2011117160A RU2011117160A RU 2011117160 A RU2011117160 A RU 2011117160A RU 2011117160/04 A RU2011117160/04 A RU 2011117160/04A RU 2011117160 A RU2011117160 A RU 2011117160A RU 2011117160 A RU2011117160 A RU 2011117160A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- substituted
- fluoro
- compound
- optionally substituted
- Prior art date
Links
- 0 C=**(c1cccc(OC(F)(F)F)c1)=C Chemical compound C=**(c1cccc(OC(F)(F)F)c1)=C 0.000 description 3
- ODXQMKCBISNKRZ-UHFFFAOYSA-N CN(C(c1cccc(C(F)(F)F)c1)=Nc1c2cccc1C(Nc1nc(CN(CC3)CC3F)ccc1)=O)C2=O Chemical compound CN(C(c1cccc(C(F)(F)F)c1)=Nc1c2cccc1C(Nc1nc(CN(CC3)CC3F)ccc1)=O)C2=O ODXQMKCBISNKRZ-UHFFFAOYSA-N 0.000 description 2
- APLKZBNJDUBCLH-UHFFFAOYSA-N CC(CO)COc1nc(NC(c2cccc3c2N=C(c2cccc(C(F)(F)F)c2)N(C)C3=O)=O)ccc1 Chemical compound CC(CO)COc1nc(NC(c2cccc3c2N=C(c2cccc(C(F)(F)F)c2)N(C)C3=O)=O)ccc1 APLKZBNJDUBCLH-UHFFFAOYSA-N 0.000 description 1
- FHLJIOYSKRKCES-UHFFFAOYSA-N CN(C(c1cccc(C(F)(F)F)c1)=Nc(c1ccc2)c2NC(c2ncccc2)=O)C1=O Chemical compound CN(C(c1cccc(C(F)(F)F)c1)=Nc(c1ccc2)c2NC(c2ncccc2)=O)C1=O FHLJIOYSKRKCES-UHFFFAOYSA-N 0.000 description 1
- VOFGSTSKBPLSOJ-UHFFFAOYSA-N CN(C(c1cccc(C(F)(F)F)c1)=Nc1c2cccc1C(Nc1cc(N3CCCC3)ncc1)=O)C2=O Chemical compound CN(C(c1cccc(C(F)(F)F)c1)=Nc1c2cccc1C(Nc1cc(N3CCCC3)ncc1)=O)C2=O VOFGSTSKBPLSOJ-UHFFFAOYSA-N 0.000 description 1
- JHPRTEBOUIZVEZ-IBGZPJMESA-N CN(C(c1cccc(C(F)(F)F)c1)=Nc1c2cccc1C(Nc1ccc(CN(CC3)C[C@H]3F)cn1)=O)C2=O Chemical compound CN(C(c1cccc(C(F)(F)F)c1)=Nc1c2cccc1C(Nc1ccc(CN(CC3)C[C@H]3F)cn1)=O)C2=O JHPRTEBOUIZVEZ-IBGZPJMESA-N 0.000 description 1
- JPSQZJVIDYOIGB-UHFFFAOYSA-N CN(C(c1cccc(C(F)(F)F)c1)=Nc1c2cccc1C(Nc1nc(CN3CCCC3)ccc1)=O)C2=O Chemical compound CN(C(c1cccc(C(F)(F)F)c1)=Nc1c2cccc1C(Nc1nc(CN3CCCC3)ccc1)=O)C2=O JPSQZJVIDYOIGB-UHFFFAOYSA-N 0.000 description 1
- KCBTVQFEDPBHQZ-UHFFFAOYSA-N CN(C(c1cccc(C(F)(F)F)c1)=Nc1c2cccc1NC(c1ncncc1)=O)C2=O Chemical compound CN(C(c1cccc(C(F)(F)F)c1)=Nc1c2cccc1NC(c1ncncc1)=O)C2=O KCBTVQFEDPBHQZ-UHFFFAOYSA-N 0.000 description 1
- MOJYHPRPKGSEJI-UHFFFAOYSA-N C[n]1nccc1C(Nc1cccc2c1N=C(c1cccc(C(F)(F)F)c1)N(C)C2=O)=O Chemical compound C[n]1nccc1C(Nc1cccc2c1N=C(c1cccc(C(F)(F)F)c1)N(C)C2=O)=O MOJYHPRPKGSEJI-UHFFFAOYSA-N 0.000 description 1
- GYPMBQZAVBFUIZ-UHFFFAOYSA-N Cc(cc1OC)ccc1OC Chemical compound Cc(cc1OC)ccc1OC GYPMBQZAVBFUIZ-UHFFFAOYSA-N 0.000 description 1
- YFKPBFKOUVIQTN-UHFFFAOYSA-N Cc(cccc1)c1OC(F)(F)F Chemical compound Cc(cccc1)c1OC(F)(F)F YFKPBFKOUVIQTN-UHFFFAOYSA-N 0.000 description 1
- UZMXDPPOKPYMPR-UHFFFAOYSA-N Cc(cccc1)c1OC(F)F Chemical compound Cc(cccc1)c1OC(F)F UZMXDPPOKPYMPR-UHFFFAOYSA-N 0.000 description 1
- DVFVNJHIVAPTMS-UHFFFAOYSA-N Cc1c(C(F)(F)F)cccc1 Chemical compound Cc1c(C(F)(F)F)cccc1 DVFVNJHIVAPTMS-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N Cc1c(C)cccc1 Chemical compound Cc1c(C)cccc1 CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- BJKUVXRAWDTVCV-UHFFFAOYSA-N FC(c1c(CC2CC2)cccc1)F Chemical compound FC(c1c(CC2CC2)cccc1)F BJKUVXRAWDTVCV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
Abstract
1. Соединение, имеющее структуру, описываемую структурной формулой (II): ! ! или его соль, где ! каждый из Z1, Z2 и Z3 независимо выбирают из N и C(R9), где ! не более чем один из Z1, Z2 и Z3 является N; ! каждый R9 независимо выбирают из водорода, галогена, -C≡N, фторзамещенного C1-C2 алкила, -O-(C1-C2) фторзамещенного алкила, -S-(C1-C2) фторзамещенного алкила, C1-C4 алкила, -S-(C1-C4) алкила, C3-C7 циклоалкила, -(C1-C2) алкил-N(R13)(R13), -O-CH2CH(OH)CH2OH, -O-(C1-C3) алкил-N(R13)(R13) и -N(R13)(R13); и ! представляет вторую химическую связь между либо W2 и C(R12), либо W1 и C(R12); ! W1 выбирают из -O-, -NH- или -N=, и ! W2(R14) выбирают из -N(R14)- и -C(R14)=, выбирая так, что ! когда W1 является -O-, один из Z1, Z2 и Z3 является N; ! когда W1 является -O- или -NH-, W2(R14) является -C(R14)= и представляет вторую химическую связь между W2 и C(R12); и ! когда W1 является -N=, W2(R14) является -N(R14)- и представляет вторую химическую связь между W1 и C(R12); ! R11 выбирают из карбоцикла и гетероцикла, где R11 необязательно замещен одним-двумя заместителями, независимо выбранными из галогена, -C≡N, C1-C4 алкила, =O, C3-C7 циклоалкила, фторзамещенного C1-C4 алкила, -O-R13, -S-R13, -(C1-C4 алкил)-N(R13)(R13), -N(R13)(R13), -O-(C1-C4 алкил)-N(R13)(R13), -(C1-C4 алкил)-O-(C1-C4 алкил)-N(R13)(R13), -C(O)-N(R13)(R13) и -(C1-C4 алкил)-C(O)-N(R13)(R13), и когда R11 является фенилом, R11 также необязательно замещен 3,4-метилендиокси, фторзамещенным 3,4-метилендиокси, 3,4-этилендиокси, фторзамещенным 3,4-этилендиокси, O-(насыщенным гетероциклом), фторзамещенным -O-(насыщенным гетероциклом) или C1-C4 алкилзамещенным O-(насыщенным гетероциклом), где ! каждый R13 независимо выбирают из водорода и -C1-C4 алкила; или два R13 вместе с атомом азота, к которому они присоединены, образуют 4-8-членный насыщенный гетероцикл, необязательно включающий один дополнительный гетероатом, �
Claims (18)
1. Соединение, имеющее структуру, описываемую структурной формулой (II):
или его соль, где
каждый из Z1, Z2 и Z3 независимо выбирают из N и C(R9), где
не более чем один из Z1, Z2 и Z3 является N;
каждый R9 независимо выбирают из водорода, галогена, -C≡N, фторзамещенного C1-C2 алкила, -O-(C1-C2) фторзамещенного алкила, -S-(C1-C2) фторзамещенного алкила, C1-C4 алкила, -S-(C1-C4) алкила, C3-C7 циклоалкила, -(C1-C2) алкил-N(R13)(R13), -O-CH2CH(OH)CH2OH, -O-(C1-C3) алкил-N(R13)(R13) и -N(R13)(R13); и
W1 выбирают из -O-, -NH- или -N=, и
W2(R14) выбирают из -N(R14)- и -C(R14)=, выбирая так, что
когда W1 является -O-, один из Z1, Z2 и Z3 является N;
когда W1 является -O- или -NH-, W2(R14) является -C(R14)= и представляет вторую химическую связь между W2 и C(R12); и
когда W1 является -N=, W2(R14) является -N(R14)- и представляет вторую химическую связь между W1 и C(R12);
R11 выбирают из карбоцикла и гетероцикла, где R11 необязательно замещен одним-двумя заместителями, независимо выбранными из галогена, -C≡N, C1-C4 алкила, =O, C3-C7 циклоалкила, фторзамещенного C1-C4 алкила, -O-R13, -S-R13, -(C1-C4 алкил)-N(R13)(R13), -N(R13)(R13), -O-(C1-C4 алкил)-N(R13)(R13), -(C1-C4 алкил)-O-(C1-C4 алкил)-N(R13)(R13), -C(O)-N(R13)(R13) и -(C1-C4 алкил)-C(O)-N(R13)(R13), и когда R11 является фенилом, R11 также необязательно замещен 3,4-метилендиокси, фторзамещенным 3,4-метилендиокси, 3,4-этилендиокси, фторзамещенным 3,4-этилендиокси, O-(насыщенным гетероциклом), фторзамещенным -O-(насыщенным гетероциклом) или C1-C4 алкилзамещенным O-(насыщенным гетероциклом), где
каждый R13 независимо выбирают из водорода и -C1-C4 алкила; или два R13 вместе с атомом азота, к которому они присоединены, образуют 4-8-членный насыщенный гетероцикл, необязательно включающий один дополнительный гетероатом, выбранный из NH, S, S(=O), S(=O)2 и O, где
когда R13 является алкилом, алкил необязательно замещен одним или более заместителями, выбранными из -OH, фтора, -NH2, -NH(C1-C4 алкила), -N(C1-C4 алкила)2, -NH(CH2CH2OCH3) и -N(CH2CH2OCH3)2, и
когда два R13 вместе с атомом азота, к которому они присоединены, образуют 4-8-членный насыщенный гетероцикл, насыщенный гетероцикл необязательно замещен на любом углеродном атоме -OH, -C1-C4 алкилом, фтором, -NH2, -NH(C1-C4 алкилом), -N(C1-C4 алкилом)2, -NH(CH2CH2OCH3) или -N(CH2CH2OCH3)2, и необязательно замещен на любом способном к замещению атоме азота -C1-C4 алкилом, фторзамещенным C1-C4 алкилом или -(CH2)2-O-CH3;
R12 выбирают из карбоцикла и гетероцикла, не являющегося тетразолилом, где R12 необязательно замещен одним или более заместителями, независимо выбранными из галогена, -C=N, C1-C4 алкила, C3-C7 циклоалкила, C1-C2 фторзамещенного алкила, -O-R13, -S-R13, -S(O)-R13, -S(O)2-R13, -(C1-C4 алкил)-N(R13)(R13), -N(R13)(R13), -O-(C1-C4 алкил)-N(R13)(R13), -(C1-C4 алкил)-O-(C1-C4 алкил)-N(R13)(R13), -C(O)-N(R13)(R13), -(C1-C4 алкил)-C(O)-N(R13)(R13), -O-фенила, фенила и второго гетероцикла, и когда R12 является фенилом, R12 также необязательно замещен 3,4-метилендиокси, фторзамещенным 3,4-метилендиокси, 3,4-этилендиокси или фторзамещенным 3,4-этилендиокси или -O-(насыщенным гетероциклом), где любой фенил, второй гетероцикл или часть из насыщенного гетероцикла в заместителе в R12 необязательно замещены галогеном; -C≡N; C1-C4 алкилом, фторзамещенным C1-C2 алкилом, -O-(C1-C2) фторзамещенным алкилом, -O-(C1-C4) алкилом, -S-(C1-C4) алкилом, -S-(C1-C2) фторзамещенным алкилом, -NH-(C1-C4) алкилом и -N-(C1-C4) алкилом;
R14 выбирают из водорода, C1-C4 алкила, C1-C4 фторзамещенного алкила, C1-C4 алкил-N(R13)(R13), C1-C4 алкил-C(O)-N(R13)(R13), C1-C4 алкил-O-R13 и C1-C4 алкил-NR13-C(O)R13; и
X1 выбирают из -NH-C(=O)-†, -C(=O)-NH-†, -NH-C(=S)-†, -C(=S)-NH-†, -NH-S(=O)-†, -S(=O)-NH-†, -S(=O)2-NH-†, -NH-S(=O)2-†, -NH-S(O)2-NR15-†, -NR15-S(O)2-NH-†, -NH-C(=O)O-†, -0C(=O)NH-†, -NH-C(=O)NR15-†, -NR15-C(=O)NH-†, -NH-NR15-†, -NR15-NH-†, -O-NH-†, -NH-O-†, -NH-CR15R16-†, -CR15R16-NH-†, -NH-C(=NR15)-†, -C(=NR15)-NH-†, -C(=O)-NH-CR15R16-†, -CR15R16-NH-C(O)-†, -NH-C(=S)-CR15R16-†, -CR15R16-C(=S)-NH-†, -NH-S(O)-CR15R16-†, -CR15R16-S(O)-NH-†, -NH-S(O)2-CR15R16-†, -CR15R16-S(O)2-NH-†, -NH-C(=O)-O-CR15R16-†, -CR15R16-O-C(=O)-NH-†, -NH-C(=O)-NR15-CR15R16-†, -NH-C(=O)-CR15R16-† и -CR15R16-NH-C(=O)-O-†, где
† обозначает место, в котором X1 соединен с R11; и
каждый R15 и R16 независимо выбирают из водорода, C1-C4 алкила, -CF3 и (C1-C3 алкил)-CF3.
3. Соединение по п.1, где X1 выбирают из -NH-C(O)-† и -C(O)-NH-†.
10. Соединение по п.1, где W2(R14) является -N(R14)- и R14 выбирают из водорода и -(C1-C4) алкила.
11. Соединение по п.1, где W2(R14) является -C(R14)- и R14 является водородом.
16. Апирогенная фармацевтическая композиция, включающая фармацевтически приемлемый носитель или разбавитель и соединение по любому из пп.1-15, или его фармацевтически приемлемую соль.
17. Способ лечения субъекта, страдающего от или подверженного резистентности к инсулину, метаболическому синдрому, диабету или его осложнениям, включающий введение субъекту, если это ему необходимо, композиции по п.16.
18. Способ повышения чувствительности к инсулину у субъекта, включающий введение субъекту, если это ему необходимо, композиции по п.16.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19457608P | 2008-09-29 | 2008-09-29 | |
US61/194,576 | 2008-09-29 | ||
PCT/US2009/058868 WO2010037129A1 (en) | 2008-09-29 | 2009-09-29 | Quinazolinone, quinolone and related analogs as sirtuin modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2011117160A true RU2011117160A (ru) | 2012-11-10 |
RU2519779C2 RU2519779C2 (ru) | 2014-06-20 |
Family
ID=42060151
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011117160/04A RU2519779C2 (ru) | 2008-09-29 | 2009-09-29 | Хиназолинон, хинолон и родственные аналоги в качестве модуляторов сиртуина |
RU2011117159/04A RU2527269C2 (ru) | 2008-09-29 | 2009-09-29 | Аналоги хроменона в качестве модуляторов сиртуина |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011117159/04A RU2527269C2 (ru) | 2008-09-29 | 2009-09-29 | Аналоги хроменона в качестве модуляторов сиртуина |
Country Status (13)
Country | Link |
---|---|
US (3) | US8987258B2 (ru) |
EP (2) | EP2342188B1 (ru) |
JP (4) | JP5611957B2 (ru) |
KR (2) | KR20110065536A (ru) |
CN (3) | CN102227420B (ru) |
AU (2) | AU2009295948B2 (ru) |
BR (2) | BRPI0919389A2 (ru) |
CA (2) | CA2738809C (ru) |
ES (2) | ES2517690T3 (ru) |
MX (2) | MX2011003373A (ru) |
RU (2) | RU2519779C2 (ru) |
SG (2) | SG196775A1 (ru) |
WO (2) | WO2010037127A1 (ru) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG190603A1 (en) | 2008-05-01 | 2013-06-28 | Sirtris Pharmaceuticals Inc | Quinolines and related analogs as sirtuin modulators |
EP2315763B1 (en) * | 2008-07-03 | 2016-06-01 | Glaxosmithkline LLC | Benzimidazoles and related analogs as sirtuin modulators |
EP2342188B1 (en) | 2008-09-29 | 2014-07-30 | GlaxoSmithKline LLC | Chromenone analogs as sirtuin modulators |
AU2010221417A1 (en) * | 2009-03-02 | 2011-09-22 | Sirtris Pharmaceuticals, Inc. | 8-substituted quinolines and related analogs as sirtuin modulators |
EP2493888B1 (en) | 2009-10-29 | 2016-04-06 | GlaxoSmithKline LLC | Bicyclic pyridines and analogs as sirtuin modulators |
CA2844670A1 (en) | 2011-08-12 | 2013-02-21 | Salk Institute For Biological Studies | Neuroprotective polyphenol analogs |
WO2013025484A1 (en) * | 2011-08-12 | 2013-02-21 | Lapchak Paul A | Polyphenol analogs to treat ischemia |
CN105796546B (zh) * | 2011-10-18 | 2020-03-03 | 株式会社爱茉莉太平洋 | 包含丁香脂素的sirt1活化剂 |
CN103086965A (zh) * | 2012-12-24 | 2013-05-08 | 金华职业技术学院 | 烟酸对乙酰氨基苯酯化合物及其合成方法 |
CA2912683A1 (en) | 2013-05-13 | 2014-11-20 | Glaxosmithkline Llc | Substituted bridged urea analogs as sirtuin modulators |
US9624211B2 (en) * | 2013-07-18 | 2017-04-18 | Board Of Regents, The University Of Texas System | Anti-cancer compounds |
US10172915B2 (en) | 2013-10-20 | 2019-01-08 | Duke University | Methods and compositions for activation of sirtuins with Annexin A1 peptides |
WO2015186068A1 (en) | 2014-06-02 | 2015-12-10 | Glaxosmithkline Intellectual Property (No.2) Limited | Preparation and use of crystalline beta-d-nicotinamide riboside |
AU2015270090A1 (en) | 2014-06-06 | 2016-12-22 | Glaxosmithkline Intellectual Property (No.2) Limited | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof |
EP3191459A1 (en) | 2014-09-05 | 2017-07-19 | AbbVie Deutschland GmbH & Co. KG | Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases |
US10457662B2 (en) | 2015-05-20 | 2019-10-29 | The Regents Of The University Of Michigan | Substituted amides for treating and preventing cancer |
WO2017003723A1 (en) | 2015-07-01 | 2017-01-05 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
JP7071917B2 (ja) | 2015-12-09 | 2022-05-19 | カデント セラピューティクス,インコーポレーテッド | ヘテロ芳香族nmda受容体モジュレーターおよびその使用 |
EP4006038A1 (en) | 2015-12-09 | 2022-06-01 | Cadent Therapeutics, Inc. | Thienopyrimidinone nmda receptor modulators and uses thereof |
RU2612875C1 (ru) * | 2015-12-14 | 2017-03-13 | Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) | Средство для ингибирования фермента тирозил-днк-фосфодиэстеразы 1 человека |
EP3426242A4 (en) * | 2016-03-11 | 2020-03-18 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | ICARITINE AND ICARITINE DERIVATIVES |
JP7332472B2 (ja) | 2016-12-22 | 2023-08-23 | ノバルティス アーゲー | Nmda受容体モジュレーターおよびその使用 |
CN106977500A (zh) * | 2017-04-17 | 2017-07-25 | 牡丹江医学院 | 一种用于治疗脑梗塞的药物及其制备方法 |
US11028068B2 (en) | 2017-07-25 | 2021-06-08 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
CN112513047B (zh) | 2018-08-03 | 2023-10-20 | 诺华股份有限公司 | 芳香杂环nmda受体调节剂及其用途 |
CR20220316A (es) | 2019-12-06 | 2022-10-07 | Vertex Pharma | Tetrahidrofuranos sustituidos como moduladores de canales de sodio |
CN113135884B (zh) * | 2020-01-20 | 2023-03-10 | 西华大学 | 一种异色烯类化合物及其制备方法和用途 |
AR121719A1 (es) | 2020-04-03 | 2022-06-29 | Petra Pharma Corp | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades |
CR20230517A (es) | 2021-05-03 | 2023-11-28 | Petra Pharma Corp | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades |
TWI829179B (zh) | 2021-05-27 | 2024-01-11 | 美商佩特拉製藥公司 | 用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑 |
CN117794920A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂 |
CN113549044B (zh) * | 2021-07-23 | 2024-01-23 | 中国药科大学 | 8-氮杂环取代色酮类衍生物及其制备方法与制药用途 |
CN113620887B (zh) * | 2021-09-14 | 2023-07-04 | 西华大学 | 一类sirt5蛋白抑制剂及其用途 |
WO2023078252A1 (en) | 2021-11-02 | 2023-05-11 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
WO2024026424A1 (en) * | 2022-07-27 | 2024-02-01 | Black Diamond Therapeutics, Inc. | Quinazolinone derivatives as and related uses |
WO2024099437A1 (en) * | 2022-11-11 | 2024-05-16 | Fochon Biosciences, Ltd. | Compounds as protein kinase inhibitors |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1108698B (de) | 1959-09-03 | 1961-06-15 | Hoechst Ag | Verfahren zur Herstellung von 2-(2'-Aminoaryl)-4, 5-arylen-1, 2, 3-triazolen |
JPS58225083A (ja) | 1982-06-23 | 1983-12-27 | Nippon Shinyaku Co Ltd | メチルフラボン誘導体 |
EP0108986A1 (en) * | 1982-11-02 | 1984-05-23 | Hokuriku Pharmaceutical Co.,Ltd | N-substituted flavone-8-carboxamides |
JPS6064976A (ja) * | 1983-09-19 | 1985-04-13 | Hokuriku Seiyaku Co Ltd | Ν−置換フラボン−8−カルボキサミド誘導体,及びその製造方法 |
US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
JPS60246384A (ja) * | 1984-05-21 | 1985-12-06 | Hokuriku Seiyaku Co Ltd | クロモン−8−カルポキサミド誘導体 |
CA1261835A (en) | 1984-08-20 | 1989-09-26 | Masaaki Toda | (fused) benz(thio)amides |
IL85554A0 (en) | 1987-03-02 | 1988-08-31 | Takeda Chemical Industries Ltd | Chromone derivatives |
US5116954A (en) | 1988-04-06 | 1992-05-26 | Lipha, Lyonnaise Industrielle Pharmaceutique | Pharmaceutically useful flavonoic compounds containing at least one substituent on the benzopyranone ring moiety |
MA21528A1 (fr) * | 1988-04-06 | 1989-12-31 | Lipha | Composants substituants du flavonoide, leurs sels, leurs manufactures et produits contenant ces matieres . |
HUT58310A (en) * | 1988-12-21 | 1992-02-28 | Upjohn Co | Anti-atherosclerotic and anti-thrombotic 1-benzopyran-4-one- and 2-amino-1,3-benzoxazin-4-one derivatives, process for producing them and pharmaceutical compositions containing them |
US5703075A (en) * | 1988-12-21 | 1997-12-30 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
RU2066322C1 (ru) * | 1991-06-28 | 1996-09-10 | Киевский Государственный Университет Им.Т.Г.Шевченко | 3-(4-метил-2-тиазолил)-6-пропил-7-(1-метил-1-этоксикарбонил)метоксихромон, обладающий гипогликемическим, гиполипидемическим действием и аналептическим действием |
IT1254469B (it) * | 1992-02-25 | 1995-09-25 | Recordati Chem Pharm | Derivati benzopiranici e benzotiopiranici |
EP0558245A1 (en) * | 1992-02-25 | 1993-09-01 | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY | Heterobicyclic compounds as antagogists of alpha-1 adrenergic and SHT1A receptors |
DE69310367T2 (de) * | 1992-07-10 | 1997-08-14 | Glaxo Lab Sa | Anilide-derivate |
GB9410207D0 (en) | 1994-05-21 | 1994-07-06 | Smithkline Beecham Plc | Process |
WO1996031206A2 (en) * | 1995-04-07 | 1996-10-10 | Warner-Lambert Company | Flavones and coumarins as agents for the treatment of atherosclerosis |
US6080757A (en) * | 1996-06-06 | 2000-06-27 | Pfizer Inc | Antibiotic quinolones and derivatives |
US6187779B1 (en) | 1998-11-20 | 2001-02-13 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives |
NZ520300A (en) | 2000-01-24 | 2004-05-28 | Kinacia Pty Ltd | Morpholino-substituted pyridopyrimidine, quinolone and benzopyranone derivatives that inhibit the enzyme phosphoinositide (PI) 3-kinase |
BR0113358A (pt) * | 2000-08-21 | 2003-07-01 | Astrazeneca Ab | Derivado de quinazolina ou de um seu sal farmaceuticamente aceitável, processo para a sua preparação, composição farmacêutica, e, uso do derivado ou de um seu sal farmaceuticamente aceitável |
JP4646626B2 (ja) * | 2002-08-16 | 2011-03-09 | アストラゼネカ アクチボラグ | ホスホイノシチド3−キナーゼβの阻害 |
US20060025337A1 (en) * | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
JP2007530417A (ja) | 2003-07-01 | 2007-11-01 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 細胞及び生物の寿命及びストレス応答を操作するための組成物 |
JP2007527418A (ja) | 2003-12-29 | 2007-09-27 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 肥満及びインシュリン耐性障害を治療又は防止するための組成物 |
FR2869615B1 (fr) * | 2004-05-03 | 2007-11-16 | Merck Sante Soc Par Actions Si | Derives de l'acide butanoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et leurs applications therapeutiques |
US20080090863A1 (en) * | 2004-09-30 | 2008-04-17 | Taisho Pharmaceutical Co., Ltd. | Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor |
WO2006094246A2 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | N-arylmethyl benzamide sirtuin modulators |
WO2006094210A2 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Tetrahydroquinoxalinone sirtuin modulators |
WO2006094248A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Aryl-substituted cyclic sirtuin modulators |
WO2006094233A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | N,n'-dicyclic isothiourea sirtuin modulators |
WO2006094236A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | N-phenyl benzamide derivatives as sirtuin modulators |
ATE544071T1 (de) | 2005-03-03 | 2012-02-15 | Sirtris Pharmaceuticals Inc | Fluoreszenzpolarisationstests für die acetyltransferase-deacetylase-aktivität |
US20070014833A1 (en) | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
US20060229265A1 (en) | 2005-03-30 | 2006-10-12 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
CA2609549A1 (en) | 2005-05-25 | 2006-11-30 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
JP2009500357A (ja) | 2005-07-07 | 2009-01-08 | サートリス ファーマシューティカルズ, インコーポレイテッド | 肥満、インスリン抵抗性障害およびミトコンドリア関連障害を処置または予防するための方法および関連する組成物 |
US8088928B2 (en) | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
WO2007019417A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Oxazolopyridine derivatives as sirtuin modulators |
US7855289B2 (en) | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
CA2631713A1 (en) | 2005-12-02 | 2007-09-13 | Sirtris Pharmaceuticals, Inc. | Modulators of cdc2-like kinases (clks) and methods of use thereof |
US8304206B2 (en) | 2005-12-02 | 2012-11-06 | Sirtris Pharmaceuticals, Inc. | Mass spectrometry assays for identifying compounds that activate deacetylases |
US20080021063A1 (en) | 2006-07-18 | 2008-01-24 | Kazantsev Aleksey G | Compositions and methods for modulating sirtuin activity |
WO2008027379A2 (en) | 2006-08-29 | 2008-03-06 | Sirtris Pharmaceuticals, Inc. | Indicators of sirtuin activity and methods of use thereof |
US20080249103A1 (en) | 2006-11-15 | 2008-10-09 | Sirtris Pharmaceuticals, Inc. | Sirtuin polymorphisms and methods of use thereof |
WO2008073451A2 (en) | 2006-12-11 | 2008-06-19 | Sirtris Pharmaceuticals, Inc. | Benzoimidazole derivatives as sirtuin (sir) modulating compounds |
WO2008100423A1 (en) | 2007-02-09 | 2008-08-21 | Sirtris Pharmaceuticals, Inc. | Gut microsomal triglyceride transport protein inhibitors |
WO2008100376A2 (en) | 2007-02-15 | 2008-08-21 | Sirtris Pharmaceuticals, Inc. | Truncation variants of sirt1 and methods of use thereof |
AU2008229385A1 (en) | 2007-03-19 | 2008-09-25 | Sirtris Pharmaceuticals, Inc. | Biomarkers of sirtuin activity and methods of use thereof |
TW200918542A (en) | 2007-06-20 | 2009-05-01 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
TW200916472A (en) | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
CA2704336A1 (en) | 2007-11-01 | 2009-05-07 | Sirtris Pharmaceuticals, Inc. | Amide derivatives as sirtuin modulators |
US20110009381A1 (en) | 2007-11-08 | 2011-01-13 | Sirtis Pharmaceuticals, Inc. | Solubilized thiazolopyridines |
JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
WO2009085226A2 (en) | 2007-12-21 | 2009-07-09 | Sirtris Pharmaceuticals, Inc. | Inhibitors of cdc2-like kinases (clks) and methods of use thereof |
US20110009496A1 (en) | 2008-01-08 | 2011-01-13 | Sirtris Pharmaceuticas, Inc. | Resveratrol formulations |
SG190603A1 (en) * | 2008-05-01 | 2013-06-28 | Sirtris Pharmaceuticals Inc | Quinolines and related analogs as sirtuin modulators |
WO2009140562A1 (en) | 2008-05-15 | 2009-11-19 | Sirtris Pharmaceuticals, Inc. | Sirt1 polymorphic variants and methods of use thereof |
KR20110019385A (ko) | 2008-05-29 | 2011-02-25 | 서트리스 파마슈티컬즈, 인코포레이티드 | 시르투인 조절제로서의 이미다조피리딘 및 관련 유사체 |
EP2315763B1 (en) | 2008-07-03 | 2016-06-01 | Glaxosmithkline LLC | Benzimidazoles and related analogs as sirtuin modulators |
AU2009282076A1 (en) | 2008-08-12 | 2010-02-18 | Sirtris Pharmaceuticals, Inc. | Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators |
EP2342188B1 (en) | 2008-09-29 | 2014-07-30 | GlaxoSmithKline LLC | Chromenone analogs as sirtuin modulators |
US20110263564A1 (en) | 2008-10-29 | 2011-10-27 | Sirtris Pharmaceuticals, Inc. | Pyridine, bicyclic pyridine and related analogs as sirtuin modulators |
BRPI0922180A2 (pt) | 2008-12-08 | 2015-12-29 | Sirtris Pharmaceuticals Inc | insoindolinona e análogos correlatos como moduladores de sirtuína |
US20130190309A1 (en) | 2008-12-16 | 2013-07-25 | Chi B. Vu | Phthalazinone and related analogs as sirtuin modulators |
EA021424B1 (ru) | 2008-12-19 | 2015-06-30 | Сертрис Фармасьютикалз, Инк. | Тиазолопиридиновые соединения, регулирующие сиртуин |
WO2010088574A1 (en) | 2009-01-30 | 2010-08-05 | Sirtris Pharmaceuticals, Inc. | Azabenzimidazoles and related analogs as sirtuin modulators |
AU2010221417A1 (en) | 2009-03-02 | 2011-09-22 | Sirtris Pharmaceuticals, Inc. | 8-substituted quinolines and related analogs as sirtuin modulators |
EP2493888B1 (en) | 2009-10-29 | 2016-04-06 | GlaxoSmithKline LLC | Bicyclic pyridines and analogs as sirtuin modulators |
WO2011116176A1 (en) | 2010-03-17 | 2011-09-22 | Sirtris Pharmaceuticals Inc. | 3-substitued imidazo (4, 5-b) pyridines and analogs as sirtuin modulators |
-
2009
- 2009-09-29 EP EP09817054.1A patent/EP2342188B1/en active Active
- 2009-09-29 US US13/121,410 patent/US8987258B2/en not_active Expired - Fee Related
- 2009-09-29 CA CA2738809A patent/CA2738809C/en not_active Expired - Fee Related
- 2009-09-29 KR KR1020117009656A patent/KR20110065536A/ko active IP Right Grant
- 2009-09-29 CN CN200980147925.6A patent/CN102227420B/zh not_active Expired - Fee Related
- 2009-09-29 MX MX2011003373A patent/MX2011003373A/es active IP Right Grant
- 2009-09-29 MX MX2011003372A patent/MX2011003372A/es active IP Right Grant
- 2009-09-29 US US13/121,411 patent/US9326986B2/en not_active Expired - Fee Related
- 2009-09-29 ES ES09817056.6T patent/ES2517690T3/es active Active
- 2009-09-29 WO PCT/US2009/058862 patent/WO2010037127A1/en active Application Filing
- 2009-09-29 CN CN201510526643.4A patent/CN105198872A/zh active Pending
- 2009-09-29 ES ES09817054.1T patent/ES2511942T3/es active Active
- 2009-09-29 AU AU2009295948A patent/AU2009295948B2/en not_active Ceased
- 2009-09-29 CN CN200980147916.7A patent/CN102227417B/zh not_active Expired - Fee Related
- 2009-09-29 JP JP2011529371A patent/JP5611957B2/ja not_active Expired - Fee Related
- 2009-09-29 BR BRPI0919389A patent/BRPI0919389A2/pt not_active IP Right Cessation
- 2009-09-29 CA CA2738794A patent/CA2738794C/en not_active Expired - Fee Related
- 2009-09-29 SG SG2013096821A patent/SG196775A1/en unknown
- 2009-09-29 AU AU2009295946A patent/AU2009295946B2/en not_active Ceased
- 2009-09-29 WO PCT/US2009/058868 patent/WO2010037129A1/en active Application Filing
- 2009-09-29 BR BRPI0919390A patent/BRPI0919390A8/pt not_active IP Right Cessation
- 2009-09-29 JP JP2011529369A patent/JP5743326B2/ja not_active Expired - Fee Related
- 2009-09-29 RU RU2011117160/04A patent/RU2519779C2/ru not_active IP Right Cessation
- 2009-09-29 EP EP09817056.6A patent/EP2344475B1/en active Active
- 2009-09-29 SG SG2013096839A patent/SG196776A1/en unknown
- 2009-09-29 KR KR1020117009658A patent/KR101679089B1/ko active IP Right Grant
- 2009-09-29 RU RU2011117159/04A patent/RU2527269C2/ru not_active IP Right Cessation
-
2014
- 2014-09-03 JP JP2014179568A patent/JP2015007106A/ja active Pending
-
2015
- 2015-01-29 US US14/608,595 patent/US20150148343A1/en not_active Abandoned
- 2015-03-24 JP JP2015061553A patent/JP2015134809A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2011117160A (ru) | Хиназолинон, хинолон и родственные аналоги в качестве модуляторов сиртутуина | |
RU2011109190A (ru) | Бензоксазолы, бензтиазолы и родственные аналоги в качестве модуляторов сиртуина | |
RU2011121655A (ru) | Производные пиридина, бициклические производные пиридина и родственные аналоги в качестве модуляторов сиртуина | |
JP2011519863A5 (ru) | ||
JP2013509442A5 (ru) | ||
RU2403258C2 (ru) | Тиазолилдигидроиндазолы | |
RU2014129742A (ru) | Производные бензолсульфонамида в качестве модуляторов rorc | |
AR082633A1 (es) | Analogos de tetraciclina | |
AR087184A1 (es) | Derivados de azaindol utiles para tratar infecciones por hiv y composiciones farmaceuticas que los contienen | |
RU2014120168A (ru) | Замещенные бициклические азагетероциклы и аналоги в качестве модуляторов сиртуина | |
JP2018535963A5 (ru) | ||
RU2006133898A (ru) | Производные бензимидазола и его применение | |
JP2015501833A5 (ru) | ||
JP2016530262A5 (ru) | ||
RU2014114466A (ru) | ИНДАЗОЛ-3-КАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ WNT/β-КАТЕНИНА | |
JP2014015465A5 (ru) | ||
RU2018112312A (ru) | Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена | |
RU2008112691A (ru) | Азотсодержащее гетероциклическое соединение и его фармацевтическое применение | |
JP2011502956A5 (ru) | ||
JP2015523334A5 (ru) | ||
JP2020506205A5 (ru) | ||
JP2020505400A5 (ru) | ||
RU2011123672A (ru) | Гетероароматические соединения для применения в качестве hif ингибиторов | |
RU2016138027A (ru) | Лечение состояний, ассоциированных с гиперинсулинемией | |
RU2013158449A (ru) | Новые фторэрголиновые аналоги |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20170930 |